---
title: "R&G Pharma released its 2024 annual performance, with a net profit attributable to the parent company of 140 million yuan, a decrease of 13.73%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/233433844.md"
description: "R&G Pharma released its 2024 annual report, with operating revenue of 744 million yuan, a year-on-year increase of 3.14%. The net profit attributable to the parent company was 140 million yuan, a year-on-year decrease of 13.73%. The net profit after deducting non-recurring gains and losses was 114 million yuan, a year-on-year decrease of 11.36%. The basic earnings per share were 1.47 yuan, and it plans to distribute a cash dividend of 1.60 yuan (including tax) for every 10 shares to all shareholders"
datetime: "2025-03-27T10:07:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/233433844.md)
  - [en](https://longbridge.com/en/news/233433844.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/233433844.md)
generator: "portal-rs"
---

# R&G Pharma released its 2024 annual performance, with a net profit attributable to the parent company of 140 million yuan, a decrease of 13.73%

According to the Zhitong Finance APP, R&G Pharma (301333.SZ) released its annual report for 2024, reporting an operating income of 744 million yuan, a year-on-year increase of 3.14%. The net profit attributable to shareholders of the listed company was 140 million yuan, a year-on-year decrease of 13.73%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 114 million yuan, a year-on-year decrease of 11.36%. The basic earnings per share were 1.47 yuan. In addition, it plans to distribute a cash dividend of 1.60 yuan (including tax) for every 10 shares to all shareholders

### Related Stocks

- [301333.CN](https://longbridge.com/en/quote/301333.CN.md)

## Related News & Research

- ['Black Swan' investor Mark Spitznagel says the crash of a lifetime is coming after one more 'euphoric rally'](https://longbridge.com/en/news/298208791.md)
- [Health Plans Have the SDoH Data. New Research Shows only 7% are Highly Effective at Using It.](https://longbridge.com/en/news/298471628.md)
- [Frontieras North America Signs LOI With Cora Terminal for Multi-Phase FASForm(TM) Deployment in Illinois](https://longbridge.com/en/news/298480137.md)
- [Corem sells Linkoping office property for SEK 160 million](https://longbridge.com/en/news/298172019.md)
- [QinetiQ partners with AVL to develop digital twin for Hurn Proving Ground vehicle testing](https://longbridge.com/en/news/298422523.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**